money moves

Houston-based carbon negative biotech startup closes series A round

The brother-sister team at Houston-based Cemvita Factory is celebrating its series A initial closing. Photo courtesy of Cemvita

A promising Houston startup using biotechnology to reduce carbon emissions is celebrating the initial closing of its series A fundraising round.

Cemvita Factory announced the news of its round closing, but didn't disclose the amount raised. 8090 Partners, a new investment group of entrepreneurs turned investors, led the round. Existing investor Oxy Low Carbon Ventures also contributed, along with Seldor Capital, Climate Capital, and others.

Founded by brother-sister team Moji and Tara Karimi in 2017, the company's technology biomimics photosynthesis to take carbon dioxide and turn it into something else. Cemvita uses this synthetic biology to decarbonize heavy industry across chemical manufacturing, mining, and oil and gas.

"Decarbonizing heavy industry is one of the most critical challenges in addressing climate change," says Moji Karimi, who serves as CEO, in a news release. "Synthetic biology is now primed to revolutionize heavy industries because of its inherent low-carbon advantages, and Cemvita is taking the lead in identifying and derisking the key applications."

Cemvita is currently working. with a number of clients — including Oxy, which announced its pilot in April — to reduce their carbon footprints.

"We believe the adoption rate and market size growth of our target applications will only accelerate due to the urgency for a low-carbon energy transition," Karimi continues. "The future of manufacturing will be low-carbon biomanufacturing and the future of mining will be sustainable biomining."

According to the release, the fresh funds will go toward launching Cemvita's bio-hydrogen solution, as well as to support construction and operation of a bio-ethylene pilot plant with Oxy. The pilot project, which reported success in the lab, is expected to scale.

"While synthetic biology has proven to be effective in re-imagining food and proteins, we've long held a firm belief in synthetic biology's promise in the heavy industrial space, but have waited until we've seen the right technology and team to drive real innovation in the sector," says Rayyan Islam, partner at 8090 Partners, in the release. "Cemvita's technology is a fundamental game-changer that provides a real economic solution and major players across heavy industry have taken serious notice."

It's not just investors and industrial players who have taken notice. Cemvita won the recent GS Beyond Energy Innovation Challenge from Cleantech.org. The company was also selected as a cohort member at Carbon2Value Initiative.

"Cemvita's technology is truly revolutionary in its use of CO2 and as a resource to provide viable economic solutions as more and more companies seek ways to reduce their carbon footprint. We remain impressed and excited about Cemvita's technology's positive impact on Earth and beyond," says Sidney N. Nakahodo, founder and general partner of Seldor Capital, in the release.

Trending News

Building Houston

 
 

Optellum and Liongard have hired two new members to their executive teams. Photos courtesy

A couple of Houston tech startups have recently announced new appointments to their C-suites. A med tech company with its national headquarters in Houston has a new leader, and a Houston software has a new exec focused on strategy.

Optellum names new CEO

Jason Pesterfield will lead United States operations for Optellum. Photo courtesy of Optellum

Optellum, a medical software startup based in the United Kingdom and has its United States HQ in Houston, has appointed Jason Pesterfield as CEO to lead growth in the U.S. clinical market. Optellum AI-based software enhances early lung cancer diagnosis and therapy with its medical device software platform, Virtual Nodule Clinic.

Pesterfield was previously the president and CEO of Veran Medical Technologies, a leader in image-guided lung cancer diagnosis. He brings 25 years of leadership experience in the medtech sector. Optellum was founded by Václav Potěšil, Lyndsey Pickup, Timor Kadir, Professor Sir Mike Brady, and Jérôme Declerck.

"It took us almost a year to find the right successor who shares our vision and has the right expertise to take Optellum on to the next stage of growth," says Potěšil in a news release. "I am really excited to work with Jason, to make Optellum's platform available to every clinician in the USA and around the world, and to help them diagnose their lung cancer patients as early as possible. With Jason on board, I can focus on advancing Optellum's vision to transform early lung cancer therapy through partnerships that harness the power of AI software combined with molecular diagnostics, robotics and interventional devices, and drugs."

Liongard announces chief strategy officer

Patrick Schneidau is the chief strategy officer for Liongard. Photo courtesy

​Houston software-as-a-service company, Liongard, has named Patrick Schneidau as chief strategy officer. The company, founded in 2015, was a 2021 InnovationMap Awards finalist and reported that the team was looking to expand by around 70 new hires over the next year.

"Liongard is an incredible Houston growth story," Schneidau tells InnovationMap. "Our founders, Joe Alapat and Vincent Tran, have built a first-class team that allow technology service providers to operate at 10x by providing unprecedented insight and data into the systems deployed in the modern IT stack. In a rapidly growing market, they are quickly becoming 'must have' technology. I'm excited to join to team to accelerate their growth into new markets and with new products."

Schneidau spent over a decade at Houston-based PROS before serving in C-level positions at two other Houston startups — Commtrex and Truss. He's also previously served as talent committee chair for Houston Exponential.

Trending News